This Project Grant award, with ID R01CA285203, is funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The $472,355 award, effective June 1, 2024, will be used by the Methodist Hospital Research Institute to explore the potential of the hepatitis C antivirals elbasvir (ELB) and daclatasvir (DAC) to sensitize and re-sensitize cancer cells to chemotherapy.
The research aims to elucidate how ELB and DAC can enhance the efficacy of chemotherapies by inhibiting drug efflux and overcoming tumor microenvironment-mediated resistance in multiple myeloma. The project will utilize cell lines, patient samples, and mouse models to investigate the mechanisms by which these antiviral drugs can improve the therapeutic effects of chemotherapies. Successful completion of the research could lead to the development of novel cancer treatment strategies that combine chemotherapy with these repurposed antiviral agents.
Generated 3/25/25, 5:14 AM